ABBVIE
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 268
- Registration Number
- NCT01834638
- Locations
- 🇺🇸
Site Reference ID/Investigator# 95395, Pico Rivera, California, United States
🇺🇸Site Reference ID/Investigator# 95387, Torrance, California, United States
🇺🇸Site Reference ID/Investigator# 95393, Houston, Texas, United States
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection
- Conditions
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 305
- Registration Number
- NCT01833533
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 571
- Registration Number
- NCT01817530
Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 673
- Registration Number
- NCT01808118
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
- Conditions
- Interventions
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 202
- Registration Number
- NCT01800695
A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT01794507
- Locations
- 🇺🇸
University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona, United States
🇺🇸Mayo Clinic /ID# 121495, Jacksonville, Florida, United States
🇦🇺Peter MacCallum Cancer Ctr /ID# 79553, Melbourne, Victoria, Australia
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 117
- Registration Number
- NCT01794520
- Locations
- 🇺🇸
Medical College of Wisconsin /ID# 205229, Milwaukee, Wisconsin, United States
🇺🇸Mayo Clinic - Rochester /ID# 74994, Rochester, Minnesota, United States
🇺🇸Mayo Clinic - Scottsdale /ID# 75808, Scottsdale, Arizona, United States
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents
- Conditions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT01783730
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 129
- Registration Number
- NCT01782495
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT01777165
- Locations
- 🇺🇸
Site Reference ID/Investigator# 87720, Gainesville, Florida, United States
🇺🇸Site Reference ID/Investigator# 83746, Jacksonville, Florida, United States
🇺🇸Site Reference ID/Investigator# 83733, Jacksonville, Florida, United States